Cargando…
Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)
BACKGROUND: This was the first large-scale prospective observational Japanese study evaluating the safety and efficacy of bevacizumab combined with paclitaxel and carboplatin for newly diagnosed advanced ovarian cancer. METHODS: Patients were prospectively enrolled in the primary analysis cohort if...
Autores principales: | Komiyama, Shinichi, Kato, Kazuyoshi, Inokuchi, Yuki, Takano, Hirokuni, Matsumoto, Takashi, Hongo, Atsushi, Asai-Sato, Mikiko, Arakawa, Atsushi, Kamiura, Shoji, Tabata, Tsutomu, Takeshima, Nobuhiro, Sugiyama, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326987/ https://www.ncbi.nlm.nih.gov/pubmed/30030657 http://dx.doi.org/10.1007/s10147-018-1319-y |
Ejemplares similares
-
Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021) -
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018) -
Perceptions and practice patterns of cancer survivorship care among Japanese gynecologic oncologists: The JGOG questionnaire survey
por: Asai-Sato, Mikiko, et al.
Publicado: (2022) -
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m(2) versus 40 mg/m(2) in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
por: Motohashi, Takashi, et al.
Publicado: (2020) -
Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)